PhRMA responds to NORD
Executive Summary
Pharmaceutical Research & Manufacturers of America maintains that its ads on the importance of patent protections for drugs to treat orphan diseases are "accurate and fair" in June 11 letter to the National Organization for Rare Diseases. "Many diseases are rare but not eligible for orphan drug status," PhRMA's response to NORD's June 6 letter states (1"The Pink Sheet" June 10, In Brief)...
You may also be interested in...
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.